Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells

Motohiko Tanino, Ryo Matoba, Seiji Nakamura, Hideto Kameda, Kouichi Amano, Toshitsugu Okayama, Hayato Nagasawa, Katsuya Suzuki, Kenichi Matsubara, Tsutomu Takeuchi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14 weeks after the first infusion. The accuracy of prediction in our study was 65.4%.

Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume387
Issue number2
DOIs
Publication statusPublished - 2009 Sep 18
Externally publishedYes

Fingerprint

Biological Factors
Gene Expression Profiling
Rheumatoid Arthritis
Leukocytes
Blood
Cells
Biomarkers
Microarrays
Biological Products
C-Reactive Protein
RNA
Inflammation
Pharmaceutical Preparations
Blood Proteins
Blood Cells
Therapeutics
Prospective Studies
Infliximab

Keywords

  • Anti-TNF-α antibody
  • Biomarker
  • C-reactive protein
  • DNA microarray
  • Gene expression
  • Infliximab
  • Methotrexate
  • Peripheral blood RNA
  • Rheumatoid arthritis
  • Transcriptome

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. / Tanino, Motohiko; Matoba, Ryo; Nakamura, Seiji; Kameda, Hideto; Amano, Kouichi; Okayama, Toshitsugu; Nagasawa, Hayato; Suzuki, Katsuya; Matsubara, Kenichi; Takeuchi, Tsutomu.

In: Biochemical and Biophysical Research Communications, Vol. 387, No. 2, 18.09.2009, p. 261-265.

Research output: Contribution to journalArticle

Tanino, Motohiko ; Matoba, Ryo ; Nakamura, Seiji ; Kameda, Hideto ; Amano, Kouichi ; Okayama, Toshitsugu ; Nagasawa, Hayato ; Suzuki, Katsuya ; Matsubara, Kenichi ; Takeuchi, Tsutomu. / Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. In: Biochemical and Biophysical Research Communications. 2009 ; Vol. 387, No. 2. pp. 261-265.
@article{f3dcd17bf6af4c8fa7b7053038efc2ca,
title = "Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells",
abstract = "Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14 weeks after the first infusion. The accuracy of prediction in our study was 65.4{\%}.",
keywords = "Anti-TNF-α antibody, Biomarker, C-reactive protein, DNA microarray, Gene expression, Infliximab, Methotrexate, Peripheral blood RNA, Rheumatoid arthritis, Transcriptome",
author = "Motohiko Tanino and Ryo Matoba and Seiji Nakamura and Hideto Kameda and Kouichi Amano and Toshitsugu Okayama and Hayato Nagasawa and Katsuya Suzuki and Kenichi Matsubara and Tsutomu Takeuchi",
year = "2009",
month = "9",
day = "18",
doi = "10.1016/j.bbrc.2009.06.149",
language = "English",
volume = "387",
pages = "261--265",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells

AU - Tanino, Motohiko

AU - Matoba, Ryo

AU - Nakamura, Seiji

AU - Kameda, Hideto

AU - Amano, Kouichi

AU - Okayama, Toshitsugu

AU - Nagasawa, Hayato

AU - Suzuki, Katsuya

AU - Matsubara, Kenichi

AU - Takeuchi, Tsutomu

PY - 2009/9/18

Y1 - 2009/9/18

N2 - Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14 weeks after the first infusion. The accuracy of prediction in our study was 65.4%.

AB - Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients has revolutionized the treatment of this disease. However, biomarkers for predicting the efficacy of the drug at an early phase of treatment for selecting real responders have not been found. We here present predictive markers based on a thorough transcriptome analysis of white blood cells from RA patients. RNA from whole blood cells of consecutive 42 patients before the first infusion was analyzed with microarrays for training studies. Samples from the subsequent 26 consecutive patients were used for a prospective study. We categorized the results into no inflammation and residual inflammation groups using the serum C-reactive protein (CRP) level at 14 weeks after the first infusion. The accuracy of prediction in our study was 65.4%.

KW - Anti-TNF-α antibody

KW - Biomarker

KW - C-reactive protein

KW - DNA microarray

KW - Gene expression

KW - Infliximab

KW - Methotrexate

KW - Peripheral blood RNA

KW - Rheumatoid arthritis

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=67949101911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67949101911&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2009.06.149

DO - 10.1016/j.bbrc.2009.06.149

M3 - Article

VL - 387

SP - 261

EP - 265

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -